Thank you for subscribing!
Finfeed Archived Dec 04, 2019
Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system.
Finfeed Archived Dec 02, 2019
Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength, excelling in the area of product development and distribution, but also forging alliances with other global, high profile medical institutions.
Finfeed Archived Nov 26, 2019
Advent Energy, in which BPH Energy (ASX:BPH) has a 25% interest, had previously interpreted significant seismically indicating gas features indicating hydrocarbon accumulation following a review in 2004.
Next Investors Archived Nov 21, 2019
HeraMED (ASX:HMD) has signed an agreement with Kinderheldin to add online midwifery service to be offered as HeraBEAT PLUS in Germany.
Get expert stock analysis direct in your inbox
Finfeed Archived Nov 19, 2019
Streamlining of the group’s internal operations and the pending Progenza licensing deal in Japan, will see Regeneus sufficiently funded to commercialisation in Japan.
Finfeed Archived Nov 18, 2019
With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Medical technology company, HeraMED Limited’s (ASX:HMD) 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) has been cleared by the US Food and Drug Administration (FDA).
Finfeed Archived Nov 14, 2019
Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength since listing on the ASX in December 2018.
Next Investors Archived Nov 14, 2019
HeraMED (ASX:HMD) has a target market of 2 million pregnancies in 2020, 6 million in 2021 and 45 million in 2022.
Join Our Mailing List
